LEX Diagnostics

Based in the United Kingdom, LEX Diagnostics is a startup. LEX Diagnostics has been acquired. Brouky classifies it under Healthcare & Life Sciences.

LEX Diagnostics developed the NULEXA ultra-fast multiplex PCR point-of-care molecular diagnostics system for rapid detection and differentiation of respiratory pathogens (Influenza A/B and SARS-CoV-2), providing a fully automated swab-to-result workflow with results in under 10 minutes and positive results reported in as little as 6 minutes. The company’s NULEXA system is CLIA-waived for use in physician offices, pharmacies and urgent care facilities.